Contraindicated the use of periciazin with dopaminergic agonists in patients without Parkinson's disease (levodopa, amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole), since there is a mutual antagonism of these drugs.
If patients with Parkinson's disease need treatment with neuroleptics, then first the dopaminergic agonists should be canceled with a gradual decrease in doses.
The use of alcohol with periciazine potentiates the sedative effect of the latter.
Pericyzazine reduces the effectiveness of amphetamine, clonidine, guanethidine.
Co-administration with sultopride increases the risk of developing ventricular arrhythmias (in particular, ventricular fibrillation).
Simultaneous use of periciazine with drugs that extend the QT interval with thiazide diuretics increases the risk of arrhythmias.
Joint use with antihypertensive drugs increases the hypotensive effect, sometimes leading to orthostatic hypotension.
Simultaneous use of pericyazine with drugs that depress the central nervous system, increases the depression of the central nervous system, increases the risk of respiratory depression.
The use of tricyclic antidepressants, MAO inhibitors, and maprotilin increases the risk of developing a malignant neuroleptic syndrome.
The appointment together with atropine and other anticholinergics leads to cumulation of undesirable effects (dry mouth, constipation, urinary retention, heat stroke).
Simultaneous use with lithium salts intensifies extrapyramidal disorders.
Pericyzazin reduces the effects of alpha and beta-adrenostimulants (epinephrine, ephedrine).
Periciazin reduces the emetic action of apomorphine, strengthens its inhibitory effect on the central nervous system.
Simultaneous use with hypoglycemic agents reduces their hypoglycemic effect.
Pericyzazin reduces the effect of funds that reduce appetite.